Notable Upgrades: Akamai Technologies (AKAM), Vertex Pharmaceuticals (VRTX), Avago Technologies (AVGO) , Threshold Pharmaceuticals (THLD), Intellipharmaceutics (IPCI)

UBS AG is out with a report this morning initiating coverage of Akamai Technologies, Inc. (AKAM) with a ‘Buy’ rating and $70 price target, implying 16% expected return. The Swiss global financial services firm said it sees the cloud services provider as the “Google of internet infrastructure.”

Akamai Technologies shares are currently priced at 37.30x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 16.46x earnings multiple. Ticker has a t-12 price/sales ratio of 6.11. EPS for the same period registers at $1.62.

AKAM closed at $60.42 a share in Thursday’s trading session. In premarket trading hours, shares of the Cambridge, Massachusetts-based company were up 0.30% at $60.60, within a 52-week range of $43.74 to $63.15.

The chart below shows where the equity has traded over the last year, with the 50-day and 200-day moving averages included.

Analysts at Goldman Sachs (GS) upgraded Vertex Pharmaceuticals Inc (VRTX) from a ‘Neutral’ rating to a ‘Buy’ rating in a research note issued to investors on Friday. The firm also raised its VRTX price target to $131 from $109, implying 43% expected return from the stock’s previous close. In its report Goldman said it sees a 90% probability of approval for the company’s VX-809/Kalydeco combo for cystic fibrosis.

Vertex pharma shares recently surged 2.40% to $93.74. The stock is up more than 21% year-over-year and has gained roughly 24% year-to-date. In the past 52 weeks, shares of Boston, Massachusetts-based company have traded between a low of $58.06 and a high of $99.74.

Vertex Pharmaceuticals Inc has a total market capitalization of $21.80 billion.

The chart below shows where the equity has traded over the last year, with the 50-day and 200-day moving averages included.

Analysts at Citigroup (C) lifted their price target on shares of Avago Technologies Ltd (AVGO) from $90.00 to $100, in a research report issued to clients on Friday. The mega bank also reiterated a ‘Buy’ rating on the shares citing increased confidence in the company’s wireless content gains after meeting with management. Citi’s new PT suggests a potential upside of 16.15% from ticker’s previous close.

Avago shares recently gained 58 cents to $86.67. The stock is up more than 122% year-over-year and $63.32% year-to-date. In the past 52 weeks, shares of the Singapore-based developer of analog semiconductor devices have traded between a low of $38.23 and a high of $87.68.

Avago Technologies Ltd has a total market capitalization of $21.67 billion.

The chart below shows where the equity has traded over the last year, with the 50-day and 200-day moving averages included.

H.C. Wainwright is out with a report this morning initiating coverage of Threshold Pharmaceuticals, Inc (THLD) with a ‘Buy’ rating and $12.00 price target, implying 205.34% expected return from the stock’s previous close of $3.93.

Threshold Pharma has a 52-week low of $3.51 and a 52-week high of $5.93. The stock of the San Francisco, California-based biotech company is down more than 9% year-over-year and $13.92% year-to-date. THLD, which is currently trading up 1 percent at $3.97, has a market cap of $237.46 million and a t-12 price-to-sales ratio of 16.96.

The chart below shows where the equity has traded over the last year, with the 50-day and 200-day moving averages included.

Shares of IntelliPharmaCeutics (IPCI) are up more than 12% to $3.04 in early trading Friday. The spike may be attributed to an upgrade to ‘Buy’ from ‘Hold’ and a $7.00 from $3.00 price target at Maxim Group, which represents expected upside of 158.30% to the stock’s previous closing price of $2.71. Maxim said the upgrade was driven by the “novel overdose deterrence technology,” which left quite an impression with the firm.

On valuation-measures, shares of IntelliPharmaCeutics have a T-12 price/sales ratio of 8.22 and a t-12 negative profit margin of (121.13%). EPS registers at ($0.39). The company has a market cap of $72 million and a median Wall Street price target of $7.75 with a high target of $11.00.

IPCI currently prints a one year return of 64.11% and a negative year-to-date return of around 19%.

The chart below shows where the equity has traded over the last year, with the 50-day and 200-day moving averages included.

Be the first to comment

Leave a Reply

Your email address will not be published.


*